One PRP treatment or a course

A course means several treatment visits

One treatment delivers the platelets prepared for that visit. A course means several visits, so the platelet totals from those visits add together. More visits still don't promise more relief. The visit count is only one part of your choice.

Clinics may use different machines or keep different blood layers. Because of that, several visits at one clinic may not equal several elsewhere. Ask about the platelet amount in each treatment and across the full course.

Knee research gives only a small reason for several visits

Some knee comparisons found a small extra benefit after several treatments. Other comparisons found no clear difference from one treatment. That evidence supports a discussion, but it doesn't settle your choice.

A knee result tells you about knees. It doesn't prove that the same visit count fits a shoulder or tendon. Your joint wear, past care, and daily needs also affect the decision. What helped one knee may not fit the soreness you have.

The exam helps choose the number of visits

Tell the clinician when soreness started and which tasks make it worse. Take along past scan pictures if they are available. Mention any medicine that affects bleeding before blood is drawn.

Keep using movement your doctor has cleared, but don't push through sharp pain. Notice whether the ache settles by the following day. Those details help you discuss the treatment count and appointment timing. You can then ask whether one visit or several has a sound reason.

Sources

1. A meta-analysis of seven high-quality randomized trials (575 patients) comparing single-dose with multiple-dose PRP for knee osteoarthritis found triple-dose PRP produced significantly better VAS scores than a single dose at 12 months (P<.0001), while double-dose did not differ significantly from single-dose at 12 months. Adverse events did not differ significantly between the double-dose or triple-dose arms and single dose.

   Tao X, Aw AAL, Leeu JJ, et al. — Three Doses of Platelet-Rich Plasma Therapy Are More Effective Than One Dose of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis. Arthroscopy, 2023. DOI: 10.1016/j.arthro.2023.05.018.

2. An earlier meta-analysis of five randomized trials (301 patients) found that at six months, single and multiple PRP injections produced similar pain improvement with no significant difference, while knee function favoured multiple injections. The two meta-analyses together support a modest functional advantage for a course of injections rather than one, without settling the number.

   Vilchez-Cavazos F, Millan-Alanis JM, Blazquez-Saldana J, et al. — Comparison of the Clinical Effectiveness of Single Versus Multiple Injections of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis. Orthopaedic Journal of Sports Medicine, 2019. DOI: 10.1177/2325967119887116.

3. A triple-blind randomized trial in 99 knees with early (KL 1-2) knee OA compared a conventional 4 mL PRP dose (mean 2.82 billion platelets) with an 8 mL 'superdose' (mean 5.65 billion), both leukocyte-depleted and prepared identically. Both groups improved on WOMAC, VAS and KOOS over six months. The trial is a direct demonstration that 'a PRP injection' is not one intervention: the same preparation at two volumes delivers a two-fold difference in platelet dose.

   Patel S, Gahlaut S, Thami T, et al. — Comparison of Conventional Dose Versus Superdose Platelet-Rich Plasma for Knee Osteoarthritis: A Prospective, Triple-Blind, Randomized Clinical Trial. Orthopaedic Journal of Sports Medicine, 2024. DOI: 10.1177/23259671241227863.

4. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.